Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05512806 · ClinicalTrials.gov registry record · Phase 1

A Bioavailability and Food Effect Study of AZD5462 in Healthy Volunteers

A Phase 1 study of Healthy Participants, sponsored by AstraZeneca.

Completed
Registry status
Phase 1
Development phase
16
Enrollment target
1
Study location

NCT05512806: Completed Phase 1 study of Healthy Participants, sponsored by AstraZeneca.

NCT05512806 is a Phase 1 study of Healthy Participants that has completed, run by AstraZeneca. The registered enrollment target is 16 participants, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05512806, a Phase 1 study of Healthy Participants, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 1
Development phase
16 participants
Enrollment target
1
Study location

Study Summary

This study will assess the pharmacokinetics of AZD5462 film-coated tablet formulation in healthy participants.

Primary Outcome

The AUCinf of a film-coated tablet of AZD5462 at 3 dose levels will be assessed.

Conditions Studied

Interventions

  • DRUG AZD5462

Study Locations (1)

Maryland

  • Research Site - Brooklyn

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2022-08-24
Est. Completion 2022-11-07
Phase Phase 1
AstraZeneca

1,285 total trials

What the finished NCT05512806 record still lists

NCT05512806 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (75% lower).

The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 1 intervention - of which AZD5462 is the first listed.

NCT05512806 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT05512806 about?

NCT05512806 is a clinical study titled "A Bioavailability and Food Effect Study of AZD5462 in Healthy Volunteers". This study will assess the pharmacokinetics of AZD5462 film-coated tablet formulation in healthy participants.

What is the current status of trial NCT05512806?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2022-08-24. Estimated completion is 2022-11-07.

What conditions does trial NCT05512806 study?

This clinical trial studies the following conditions: Healthy Participants.

What interventions are being tested in trial NCT05512806?

The interventions under investigation include: AZD5462 (DRUG).

Who is sponsoring clinical trial NCT05512806?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05512806 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Participants

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05512806's enrollment target sits among peer trials

16 97th of 119 higher than 16 of 119 other Healthy Participants trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy Participants trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05512806, the US trial registry maintained by the National Library of Medicine. NCT05512806 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.